A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
István Peták, Maud Kamal, Anna Dirner, Ivan Bièche, Róbert Dóczi, Odette Mariani, Péter Filotás, Anne Vincent‐Salomon, Barbara Vodicska, Vincent Servois, Edit Várkondi, David Gentien, Dóra Tihanyi, Patricia Tresca, Dóra Lakatos, Nicolas Servant, Júlia Déri, Pauline du Rusquec, Csilla Hegedüs, Diana Bello Roufai, Richard B. Schwab, Célia Dupain, István Vályi‐Nagy, Christophe Le Tourneau
Abstract
Precision oncology is currently based on pairing molecularly targeted agents (MTA) to predefined single driver genes or biomarkers. Each tumor harbors a combination of a large number of potential genetic alterations of multiple driver genes in a complex system that limits the potential of this approach. We have developed an artificial intelligence (AI)-assisted computational method, the digital drug-assignment (DDA) system, to prioritize potential MTAs for each cancer patient based on the complex individual molecular profile of their tumor. We analyzed the clinical benefit of the DDA system on the molecular and clinical outcome data of patients treated in the SHIVA01 precision oncology clinical trial with MTAs matched to individual genetic alterations or biomarkers of their tumor. We found that the DDA score assigned to MTAs was significantly higher in patients experiencing disease control than in patients with progressive disease (1523 versus 580, P = 0.037). The median PFS was also significantly longer in patients receiving MTAs with high (1000+ <) than with low (<0) DDA scores (3.95 versus 1.95 months, P = 0.044). Our results indicate that AI-based systems, like DDA, are promising new tools for oncologists to improve the clinical benefit of precision oncology.